HT
Hisamitsu Pharmaceutical Co., Inc.
HTSUF · OTC
$29.00 +0.00% (+$0.00)
Market Cap ¥325.1B
P/E Ratio 18.50x
Div. Yield 2.84%
ROE 8.55%
Bulios Fair Price
$18.2
37.2% downside
Current Price
$29
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HTSUF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
5/9Valuation
63 /100
Fair P/B 1.11x
P/S 2.53x
P/E 18.50x
Growth
73 /100
Growing Book val. growth 1.63%
FCF growth 39.42%
EPS growth 17.06%
Profitability
53 /100
Moderate FCF margin 0.00%
Op. margin 11.21%
Gross margin 57.05%
Quality
31 /100
Poor Asset turnover 0.35x
ROA 4.88%
ROIC 4.04%
Debt
100 /100
Low Net debt/EBITDA -7.39x
Int. coverage 2,381.26x
Debt/Equity 0.01x
Stability
81 /100
Stable Profitable years 6
EPS volatility 10.71%
Beta 0.29x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HTSUF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Kazuhide Nakatomi
Employees
2,759
Headquarters
Tosu